The raison d'étre for the drug discovery and development process is to provide safe and effective treatments for diseases. Bringing a new drug to market, however, is a time-consuming and expensive process and it remains an imperative for drug companies that they identify ways in which they can accelerate the identification of potential targets and their screening and development in order to maintain a competitive edge. Successful drug discovery efforts include biochemical, biophysical, genetic and immunological approaches, targeting such processes as signal transduction, cell cycle control, apoptosis, gene regulation and metastasis. As the number of these biological targets increases, reliance on bioinformatics and chemoinformatics to improve decision making, by identifying characteristics of successful drugs and sharing knowledge gained within the scientific community, has become a burgeoning area in the post-genomic era of drug discovery.
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Dr Marcel van Duin of Organon Research Laboratories set the scene of the colloquium by describing how genome mining can be linked and integrated with well-defined analysis of disease processes for in vitro and in vivo models to successfully validate potential targets in atherosclerosis. Dr Eric Schadt (Rosetta) presented novel ways to rapidly identify causal genes and expression patterns associated with common human diseases. Dr Scott Kahn (Accelrys) presented an overview of the computational approaches used to facilitate data storage and access, and his talk explored the technologies of in silico prediction and integration with experimental and biological data, and how this knowledge might be shared.
Dr Adele Rowley (Cellzome) covered the vast area concerned with the identification and validation of target molecules, in particular proteins instrumental in disease processes, and of particular pathways. Her talk described the new technologies to rapidly define protein interactions and how disease targets must considered within the fullest context possible of cellular interactions.
The nature of the target biomolecule and its structure was developed by Dr Adrian Gill (Astex Technology) in his presentation on structure-based drug discovery. Dr Gill discussed the use of high-throughput X-ray crystallographybased screening, combined with in silico structure-based design programmes to screen compound sets with protein crystals. Dr Steven Holmes of Oxford Glycosciences focused on the design and clinical use of recombinant antibodies for cancer therapy and the technologies of phage display and human antibody-engineered mice to create a vast array of novel antibody-based therapeutics.
Returning to the theme of increasing reliance on bioinformatics and chemoinformatics Dr Malcolm Weir (Inpharmatica) addressed the future of drug-discovery processes and how an integrated, knowledge-based approach can improve the search and successful discovery of so-called 'druggable targets'.
